Prevalence of &lt;i&gt;Helicobacter pylori &lt;/i&gt;Antibodies in Patients on Chronic Intermittent Haemodialysis

Rj, Loffeld; Hg, Peltenburg; H, vd Oever; Stobberingh, Ellen E.

doi:10.1159/000186560

Cited by 26 publications

(26 citation statements)

References 8 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A striking feature in the antral biopsies was the absence of the organism in the areas with intestinal metaplasia, even when there was colonization of the adjacent surface epithelium. A similar observation in nonuremic patients has been reported pre viously [27], H. pylori were not seen overlying normal duodenal mucosa or foci of intestinal metaplasia within the stomach [27,28], while they may be seen within the duodenum in association with gastric metaplasia of the mucosa [29,30], Furthermore, in uremic patients Wee et al [21] reported that in all patients in whom H. pylori-like organisms occurred in the duodenal cap, gastric metapla sia was present.…”

Section: Resultssupporting

confidence: 77%

Helicobacter pyloriand Uremic Gastritis: A Histopathologic Study and a Correlation with Endoscopic and Bacteriologic Findings

Moustafa

Khalil²,

Wahab³

et al. 1997

Am J Nephrol

View full text Add to dashboard Cite

In this work 70 asymptomatic uremic patients under maintenance hemodialysis in our institution underwent upper-gastrointestinal endoscopy as part of a routine investigation prior to kidney transplantation. Their endoscopic findings were scored and antral mucosal biopsies were obtained and subjected to histopathologic and bacteriologic assessment. Bacteriologic examination included culture, rapid urease test, and microscopic examination for detection of Helicobacter pylori. Histopathologic examination of the gastric mucosa showed chronic superficial gastritis in 52%, atrophic gastritis in 5.7% and intestinal metaplasia in 37% of the cases. Of the cases with superficial gastritis, 5 showed in addition gastric mucosal dysplastic changes. There was no correlation between the histopathologic and endoscopic findings. Nevertheless, there was a significant association between histopathologic changes and H. pylori infection (p = 0.0001). All cases with atrophic gastritis showed H. pylori, and of 24 cases with chronic active superficial gastritis. H. pylori was detected in 18, while it was detected in only 2 of 13 cases with chronic inactive superficial gastritis and in 4 of 29 cases with normal antral mucosal biopsies. Among different variables in dialysis patients, only patients’ ages were found to have significant association with H. pylori infection (p < 0.03). We have concluded that in asymptomatic uremic patients under maintenance hemodialysis, relying only on endoscopy for critical assessment of the upper gastrointestinal tract is unsatisfactory and histopathologic examination of the antral mucosal biopsies is mandatory. Chronic superficial gastritis and atrophic gastritis should be expected in up to 60% of the patients, and there is a strong association between H. pylori infection and gastritis.

show abstract

Section: Resultssupporting

confidence: 77%

Helicobacter pyloriand Uremic Gastritis: A Histopathologic Study and a Correlation with Endoscopic and Bacteriologic Findings

Moustafa

Khalil²,

Wahab³

et al. 1997

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…The current authors surveyed and summarized the previous studies that studied the prevalence of H. pylori infection in patients receiving hemodialysis (see Table 1). [12,[18][19][20][21][22][23][24][25][26][27][28] In the present study, 40.3% of hemodialysis patients were infected with H. pylori. Considering that the prevalence of H. pylori infection has been reported to be higher than 70% among Japanese adults over 50 years of age, [29] these results indicate the relative percentage of H. pylori-positive hemodialysis patients could be lower than the general patient population.…”

Section: Discussionsupporting

confidence: 47%

“…Previously, it has been reported that there was no difference in the prevalence of H. pylori infection in dialysis patients in regard to age, dialysis period, or the timing of symptom appearance. [32] It has been shown that H. pylori eradication regimens with higher antibiotic dosages provide a higher incidence [18] Netherland No description No description 30 43 Serology Jaspersen D (1995) [19] Germany 127 37 34 20.6 UBT, histology Luzza F (1996) [20] Italy 103 78 103 73 Serology Abu Farsakh NA (1996) [21] Jordan 100 73 92 48.9 Histology…”

Section: Discussionmentioning

confidence: 99%

Eradication ofHelicobacter pyloriin Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

Background. Helicobacter pylori (H. pylori) are a causative agent of digestive disease. Although a proton pump inhibitor combined with amoxicillin-clarithromycin is the accepted drug treatment for H. pylori eradication in Japan, there is no consensus treatment for hemodialysis patients. Study. Seventy-seven hemodialysis patients underwent upper digestive tract endoscopy. Biopsy specimens were taken, and histological findings, culture, and rapid urease tests were performed to confirm the presence of H. pylori. H. pylori-positive patients were then administered at random either a seven-day lansoprazole (60 mg a day)-amoxicillin (750 mg a day)-clarithromycin (400 mg a day) (LAC) regimen or a seven-day lansoprazole (60 mg a day)-clarithromycin (400 mg a day) (LC) regimen. The success of H. pylori eradication was determined from histological findings, culture, and rapid urease tests. Results. In 13 of 77 patients (13.6%), ulcers and/or ulcer scars were seen by endoscopy. Thirty-one patients (40.3%) were positive for H. pylori, and 20 patients among them were randomized to one of two regimens: one is seven-day LAC regimen (eleven patients) and the other is seven-day LC regimen (nine patients). Eradication was successful in nine of the eleven patients (72.7%) receiving the LAC regimen, but in only three of the nine patients (33.3%) who underwent the LC regimen. No serious adverse effects were observed with either regimen, and 95% of the patients reported complete compliance. Conclusion. A seven-day low dose LAC regimen is safe and effective and recommended for treatment of H. pylori infection in hemodialysis patients.

show abstract

“…In dialysed patients, the incidence of ulcer is similar to that in patients who do not receive dialysis [5,6]. However, it has been reported that the prevalence of H. pylori infection is lower in dialysed patients [7][8][9]. We investigated the backgrounds of patients receiving dialysis and showing a low prevalence of H. pylori infection.…”

Section: Introductionmentioning

confidence: 96%

Helicobacter pylori in Patients Receiving Long-Term Dialysis

Nakajima

Sakaguchi²,

Amemoto³

et al. 2002

Am J Nephrol

View full text Add to dashboard Cite

Background:Helicobacter pylori (H. pylori) is considered to cause gastritis and gastric ulcer. In dialysis patients, digestive tract hemorrhage is sometimes fatal. However, in regard to H. pylori infection in patients with end-stage renal disease (ESRD), many issues remain to be clarified. Methods: This study included 76 symptom-free patients with ESRD. The subjects consisted of 25 patients with chronic renal failure who had not received dialysis and 51 patients receiving dialysis. On upper digestive tract endoscopy, specimens were taken for analysis of H. pylori. Urease test, culture, and microscopy were performed. Results: In non-dialysed patients, the prevalence of H. pylori-positive patients was 56.0%. In dialysed patients, the percentage was significantly lower (27.5%). In dialysed patients, the mean duration of dialysis was 8.1 ± 7.5 months (mean ± SD) in H. pylori-positive patients and 56.2 ± 60.9 months (mean ± SD) in H. pylori-negative patients (p < 0.001). 11 of 13 non-dialysed patients with chronic gastritis were positive for H. pylori. However, only 5 of 24 dialysed patients were positive for H. pylori infection. Conclusions: Long-term dialysis decreased the prevalence of H. pylori. The reduction of gastric acid secretion related to chronic gastritis may be involved.

show abstract

Prevalence of <i>Helicobacter pylori </i>Antibodies in Patients on Chronic Intermittent Haemodialysis

Cited by 26 publications

References 8 publications

<i>Helicobacter pylori</i>and Uremic Gastritis: A Histopathologic Study and a Correlation with Endoscopic and Bacteriologic Findings

<i>Helicobacter pylori</i>and Uremic Gastritis: A Histopathologic Study and a Correlation with Endoscopic and Bacteriologic Findings

Eradication ofHelicobacter pyloriin Hemodialysis Patients

<i>Helicobacter pylori</i> in Patients Receiving Long-Term Dialysis

Contact Info

Product

Resources

About